At some point this bull market in all things health care will fade out, and I wonder if Pfizer (NYSE:PFE) shares will maintain this sort of valuation when that occurs. With the spin-off of Zoetis (NYSE:ZTS),
years of restructuring, and a reorganization that will create
“innovative” and “value” cores, I have to think that Pfizer management
has pulled every trick out of its bag aside from a full break-up of the
company. What's more, while there are some worthwhile products in the
pipeline, I think the company is looking at pretty sluggish long-term
growth as those new products will struggle to offset the loss of
exclusivity on other lucrative drugs.
Read more here:
http://www.investopedia.com/stock-analysis/073013/pfizer-looking-little-tired-pfe-abbv-celg-rhhby.aspx
No comments:
Post a Comment